Amicus Therapeutics, headquartered in Philadelphia, PA, is a leading biotechnology company with a global presence. With offices across the globe, they are dedicated to developing advanced therapies to treat rare and devastating diseases. Amicus Therapeutics offers a range of products and services aimed at improving the lives of patients with rare diseases.

Their pipeline includes treatments for Fabry Disease, Pompe Disease, Batten Disease, and additional preclinical programs. One of their renowned products is Galafold® (migalastat), a treatment for Fabry Disease. Committed to patient advocacy, Amicus Therapeutics provides expanded access programs and patient advisory boards to ensure the voice of the patient is heard.

They also offer a wealth of resources, including rare disease stories and information, to support patients and their families. Driven by responsibility and ethics, Amicus Therapeutics has a global medical affairs team that ensures the safety and efficacy of their treatments. The company is also actively involved in corporate giving initiatives, aiming to make a positive impact beyond disease.

For investors and the media, Amicus Therapeutics offers reliable investor relations, press releases, events, and presentations to keep stakeholders informed. With a focus on innovation and a dedication to improving the lives of patients, Amicus Therapeutics is at the forefront of biotechnology research and development. Contact them today to learn more about their groundbreaking therapies